PT-141 (Bremelanotide) vs AHK-Cu
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →AHK-Cu
AHK-Cu (Copper Tripeptide-3, Alanine-Histidine-Lysine Copper) is a copper peptide similar to GHK-Cu but with different properties. It's used for hair growth and skin rejuvenation applications.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | AHK-Cu |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | The copper-binding tripeptide stimulates collagen synthesis and may promote hair follicle enlargement. Works similarly to GHK-Cu but may have distinct receptor interactions. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Topical: 0.5-2% concentration in serums for skin or scalp applications. Often combined with other growth factors for hair formulations. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Topical application to skin or scalp. Can be used with microneedling for enhanced penetration. May cause temporary blue-green tint at high concentrations. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Generally well-tolerated. May cause skin irritation in sensitive individuals. Temporary discoloration possible. |
| Best For |